q1 loss per share $0.84.
q3 adjusted loss per share $0.54 excluding items.
q3 sales $351.9 million versus refinitiv ibes estimate of $298.1 million.
qtrly sales, excluding surcharge, were flat sequentially on 5% lower volume.
compname reports second quarter 2021 results; reaffirms full year 2021 guidance; announces $130 million share repurchase program.
q3 sg&a expenses $47.8 million versus refinitiv ibes estimate of $48.7 million.
qtrly medical end-use sales increased 7% sequentially.
for the balance of year, we currently expect to be in range of 28% to 30% tax rate.